Novo Nordisk’s $4.1B Clayton Facility to Add 1,000 Jobs by Mark Eisenberg 25.06.2024 Novo Nordisk's $4.1B Clayton investment creates 1,000 jobs, boosts local economy, and enhances life science growth in North Carolina.
Lilly’s Zepbound Resolves Sleep Apnea in 52% of Patients by Mark Eisenberg 22.06.2024 Eli Lilly's Zepbound reduces sleep apnea by up to 52% in trials, showing promise beyond weight loss. FDA approval for ...
JPMorgan: Defensive Sectors Leading Q2 Gains in Europe by Terry Bingman 17.06.2024 JPMorgan predicts continued outperformance of defensive sectors like Utilities, Real Estate, and Staples into Q3, favoring them over cyclical stocks.
Roche’s Hemlibra Battles Fierce Competition Amid Rating Hold by Mark Eisenberg 17.06.2024 Roche's Hemlibra braces for fierce competition from Novo Nordisk's mim8, as analysts give mixed ratings and forecasts on Roche's strategic ...
Novo Nordisk CEO to Testify on High Prices of Ozempic, Wegovy by Mark Eisenberg 15.06.2024 Senate subpoenas Novo's Langa over drug pricing; Jorgensen to testify in September as Novo blames U.S. health system for high ...
Altimmune’s Promising GLP-1 Drug: Worth the Investment? by Mark Eisenberg 25.04.2024 Altimmune's stock has seen a strong increase in value, surpassing Eli Lilly and Novo Nordisk. However, there are risks involved.
Pfizer’s Debt Concerns Cast Doubt on Viking Therapeutics Acquisition by Mark Eisenberg 01.04.2024 Pfizer's interest in the weight loss market is uncertain due to its significant debt of over $70 billion and recent ...
IPhone and Tesla Sales Plummet in China: What You Need to Know by Lilu Anderson 06.03.2024 Sales of iPhones and Teslas have slumped in China, while the success of the maker of Ozempic and Wegovy is ...
UK Pharma Complaints Delay: Public Health at Risk? by Mark Eisenberg 19.02.2024 Investigation reveals significant delays in processing complaints against UK drug companies, raising concerns about patient safety and public health. Increased ...
Eli Lilly and Novo Nordisk Lead Pharma Surge by Mark Eisenberg 17.02.2024 The weight-loss drugs of Eli Lilly and Novo Nordisk have led to soaring share prices as investors anticipate high demand ...